Qingyuan Zhang

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne et al. · Journal of Clinical Oncology · 2021 · 252 citations · Full text

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

Yuankai Shi, Hang Su, Yongping Song et al. · The Lancet Haematology · 2019 · 233 citations

Lymphoid Neoplasia, Medicine, Immunotherapy +2

A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Yuqin Song, Jianqiu Wu, Xinchuan Chen et al. · Clinical Cancer Research · 2019 · 154 citations

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Matthew J. Matasar, Marcelo Capra, Muhıt Özcan et al. · The Lancet Oncology · 2021 · 132 citations · Full text

Lymphoid Neoplasia, Medicine, Pharmacology +7

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Magdalena Klánová, Laurie H. Sehn, Isabelle Bence‐Bruckler et al. · Blood · 2019 · 124 citations · Full text